Clinical Trial: Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
Study Status: Completed
Recruit Status: RECRUITING
Condition: Obstructive Sleep Apnea
Study Type: INTERVENTIONAL
Official Title: Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
Brief Summary:
This is an open-label study of the combination of atomoxetine and oxybutynin (ato-oxy) in children with Down syndrome and obstructive sleep apnea (OSA) documented by polysomnography (PSG).Participants will receive ato-oxy for 6 months.Ato-oxy dose will be 5 mg oxybutynin and 0.5mg/kg/day (max 40 mg) atomoxetine.Dosing of the study treatment will occur approximately 30 minutes prior to bedtime.Participants who withdraw from the study will not be replaced.Study participants will undergo eligibility…
Read more